Allstate Corp Purchases 4,533 Shares of Johnson & Johnson $JNJ

Key Points

• Allstate increased its Johnson & Johnson position by 1.8% in the second quarter, purchasing 4,533 shares for a total holding of 249,928 shares valued at approximately $63.5 million.
• Johnson & Johnson reported quarterly EPS of $2.90, beating expectations, while revenue rose 6.6% year over year to $25.31 billion. The company also declared a quarterly dividend of $1.34 per share, equivalent to a 1.9% annual yield.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $272.83, though elevated valuation, recent insider selling and unresolved talc litigation pose risks.

Allstate Corp grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.8% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 249,928 shares of the company's stock after purchasing an additional 4,533 shares during the quarter. Johnson & Johnson makes up approximately 0.6% of Allstate Corp's holdings, making the stock its 22nd biggest position. Allstate Corp's holdings in Johnson & Johnson were worth $63,474,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. OMERS ADMINISTRATION Corp grew its position in Johnson & Johnson by 139.9% during the second quarter. OMERS ADMINISTRATION Corp now owns 511,025 shares of the company's stock valued at $129,785,000 after buying an additional 297,978 shares during the period. Leigh Baldwin & CO. LLC boosted its stake in shares of Johnson & Johnson by 4.0% during the 2nd quarter. Leigh Baldwin & CO. LLC now owns 2,262 shares of the company's stock worth $574,000 after acquiring an additional 87 shares during the last quarter. Seros Financial LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $217,000. Clal Insurance Enterprises Holdings Ltd grew its position in shares of Johnson & Johnson by 51.9% during the 2nd quarter. Clal Insurance Enterprises Holdings Ltd now owns 228,108 shares of the company's stock valued at $57,933,000 after acquiring an additional 77,970 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Johnson & Johnson by 7.4% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 307,423 shares of the company's stock worth $78,076,000 after purchasing an additional 21,189 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $275.12 on Friday. Johnson & Johnson has a 52 week low of $173.33 and a 52 week high of $281.07. The business's 50 day moving average price is $261.98 and its 200 day moving average price is $245.07. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The firm has a market cap of $663.01 billion, a P/E ratio of 31.88, a P/E/G ratio of 2.66 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analysts' expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business's quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. Johnson & Johnson's payout ratio is currently 62.11%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on JNJ shares. Scotiabank reissued an "outperform" rating and set a $305.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. HSBC set a $290.00 price target on shares of Johnson & Johnson and gave the company a "buy" rating in a report on Monday, July 6th. Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 3rd. Finally, UBS Group initiated coverage on Johnson & Johnson in a research note on Wednesday. They issued a "buy" rating and a $320.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $272.83.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst sentiment remains supportive. JNJ received an upgrade that helped it reach a new 12-month high, while the broader analyst view is rated “Moderate Buy.” UBS also began coverage, potentially increasing institutional attention. Johnson & Johnson Reaches New 12-Month High Following Analyst Upgrade Johnson & Johnson Receives Average Rating of Moderate Buy
• Positive Sentiment: Johnson & Johnson’s 64-year record of dividend growth remains a key support for income-oriented investors. Strong profitability and the company’s diversified healthcare portfolio help sustain the dividend despite competitive pressure on a major drug. Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect
• Neutral Sentiment: Management will discuss the business at the Deutsche Bank Healthcare Summit on September 17. The event could provide updates on pharmaceuticals, litigation and forward guidance, but it is not itself a change to earnings expectations. Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
• Negative Sentiment: Profit-taking and valuation risk are elevated after JNJ gained about 60% over the past year versus roughly 21% for the S&P 500. Analysts question whether the current price already discounts growth above management’s near-term outlook. Was JNJ Stock Rally Actually Its Own? Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?
• Negative Sentiment: An executive vice president sold 33,597 shares worth approximately $9.2 million, reducing his holdings by 56.9%. The sale may reinforce short-term concerns about insider conviction, although it does not change JNJ’s fundamentals. SEC insider transaction filing
• Negative Sentiment: An analyst lowered the FY2026 EPS forecast, adding pressure to expectations. Talc litigation also remains unresolved despite a proposed path toward settlement, while the Louisiana verdict continues to focus attention on legal liability and potential costs. Johnson & Johnson dividend and competition analysis

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kathryn Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares of the company's stock, valued at $27,560,551.20. The trade was a 8.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 97,569 shares of company stock valued at $25,476,044 in the last 90 days. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.